ArticleEndocrine2025
Metabolic phenotype in non-aldosterone producing adrenal adenomas with co-existent polycystic ovary syndrome: a joint Ens@t project.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Prevalence of Second Neoplasms in Patients with Non-Aldosterone Producing Adrenocortical Lesions.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-aldosterone producing-adrenal-adenomas (NAPACAs) and polycystic ovary syndrome (PCOS) are associated with insulin-resistance (IR). Whether the co-existence of the two diseases leads to accentuated adverse metabolic profile remains unknown. Aim of this study is the assessment of cardiometabolic risk factors in women with NAPACAs with and without PCOS.
methodsWe conducted a retrospective multicenter study including adult premenopausal women categorized as NAPACA (n = 45), PCOS (=20) or NAPACA+PCOS (n = 24), excluding women with hormonally active adenomas, congenital-adrenal-hyperplasia, diabetes, systemic steroid medication or active malignancy.
resultsNAPACA patients were significantly older than the other two groups (P < 0.001). All groups did not differ in blood pressure, HbA1c, fasting plasma glucose (P > 0.05) or in body-mass-index (P = 0.06). NAPACA+PCOS patients displayed significantly increased insulin resistance (IR) (GIR:P < 0.05, HOMA: P < 0.05, QUICKI:P < 0.05, MATSUDA-index: P < 0.05). Cortisol levels upon 1-mg-dexamethasone-suppression-test (DST) did not differ among the groups; DHEA-S (P < 0.05) and testosterone (P < 0.01) were significantly higher in the two groups with PCOS patients. Free-androgen-index positively correlated with IR in NAPACA (GIR P < 0.01, HOMA P < 0.05, QUICKI P < 0.05) and PCOS (GIR P < 0.01, HOMA P < 0.01, QUICKI P < 0.01, MATSUDA P < 0.01), while 1mg-DST positively correlated with IR in NAPACA+PCOS (GIR P = 0.05, HOMA P < 0.05, QUICKI P < 0.05, MATSUDA P < 0.05). Younger age, higher IR and lower HDL levels predicted the PCOS presence in NAPACA patients whereas the multivariate analysis revealed age and HDL levels as the most important predictors of this association.
conclusionThese findings provide evidence for a distinct metabolic pattern in NAPACA+PCOS patients compared to NAPACA patients. Further prospective studies with larger patient cohorts will be necessary to elucidate this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.